'Hot phase' non-dilated left ventricular cardiomyopathy with atypical onset and recurrence: a case report.
Cardiac magnetic resonance
Cardiomyopathy
Endomyocardial biopsy
Multimodality imaging
Journal
ESC heart failure
ISSN: 2055-5822
Titre abrégé: ESC Heart Fail
Pays: England
ID NLM: 101669191
Informations de publication
Date de publication:
12 Jul 2024
12 Jul 2024
Historique:
revised:
18
03
2024
received:
21
10
2023
accepted:
02
04
2024
medline:
13
7
2024
pubmed:
13
7
2024
entrez:
13
7
2024
Statut:
aheadofprint
Résumé
Non-dilated left ventricular cardiomyopathy (NDLVC) is a newly categorized cardiomyopathy phenotype includingseveral aetiologies with a linking characteristic represented by the normal left ventricular volume. Inflammatory heart disease (InHD) is a heterogeneous process with variegate clinical manifestations, sometimes in overlap with NDLVC. A 26-year-old woman was admitted forcomplete heart block (CHB) and persistently raised troponin. Echocardiography and coronary angiography were normal. Extensive oedema and late gadolinium enhancement was found at cardiac magnetic resonance. Endomyocardial biopsy showed no signs of active myocarditis. Steroid therapy was started with restoration of atrioventricular conduction but subsequently the patient experienced a mild recurrence with a new troponin relapse. Genetic test was negative for mutations related with the clinical scenario. In this case of NDLVC with InHD the precise diagnostic work-up, including genetic test, was crucial for diagnostic, prognostic andtherapeutic purposes. Multimodality approach is crucial to detect and treat possible recurrences.
Types de publication
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024 The Authors. ESC Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
Références
Elena Arbelo E, Protonotarios A, Gimeno JR, Arbustini E, Barriales‐Villa R, Basso C, et al. ESC Scientific Document Group. 2023 ESC Guidelines for the management of cardiomyopathies: Developed by the task force on the management of cardiomyopathies of the European Society of Cardiology (ESC). Eur Heart J 2023;44:3503‐3626. doi:10.1093/eurheartj/ehad194
Myocarditis BC. N Engl J Med 2022;387:1488‐1500. doi:10.1056/NEJMra2114478
Ammirati E, Frigerio M, Adler ED, Basso C, Birnie DH, Brambatti M, et al. Management of acute myocarditis and chronic inflammatory cardiomyopathy: an expert consensus document. Circ Heart Fail 2020;13:e007405. doi:10.1161/CIRCHEARTFAILURE.120.007405
Smith ED, Lakdawala NK, Papoutsidakis N, Aubert G, Mazzanti A, McCanta AC, et al. Desmoplakincardiomyopathy, a fibrotic and inflammatory form of cardiomyopathy distinct from typical dilated or arrhythmogenic right ventricular cardiomyopathy. Circulation 2020;141:1872‐1884. doi:10.1161/CIRCULATIONAHA.119.044934
Peretto G, Casella M, Merlo M, Benedetti S, Rizzo S, Cappelletto C, et al. Inflammation on endomyocardial biopsy predicts risk of MACE in undefined left ventricular arrhythmogenic cardiomyopathy. JACC Clin Electrophysiol 2022;9:951‐961. doi:10.1016/j.jacep.2022.10.032
Cipriani M, Merlo M, Gabrielli D, Ammirati E, Autore C, Basso C, et al. ANMCO/SIC consensus document on the management of myocarditis. G Ital Cardiol 2020;21:969‐989. doi:10.1714/3472.34551
Ogunbayo GO, Elayi SC, Ha LD, Olorunfemi O, Elbadawi A, Saheed D, et al. Outcomes of heart block in myocarditis: a review of 31,760 patients. Heart Lung Circ 2019;28:272‐276. doi:10.1016/j.hlc.2017.12.005
Ammirati E, Buono A, Moroni F, Gigli L, Power JR, Ciabatti M, et al. State‐of‐the‐art of endomyocardial biopsy on acute myocarditis and chronic inflammatory cardiomyopathy. Curr Cardiol Rep 2022;24:597‐609. doi:10.1007/s11886‐022‐01680‐x
Frustaci A, Russo MA, Chimenti C. Randomized study on the efficacy of immunosuppressive therapy in patients with virus‐negative inflammatory cardiomyopathy: the TIMIC study. Eur Heart J 2009;30:1995‐2002. doi:10.1093/eurheartj/ehp249
Chimenti C, Russo MA, Frustaci A. Immunosuppressive therapy in virus‐negative inflammatory cardiomyopathy: 20‐year follow‐up of the TIMIC trial. Eur Heart J 2022;43:3463‐3473. doi:10.1093/eurheartj/ehac348
Heusch A, Kühl U, Rammos S, Krogmann ON, Schultheiss HP, Bourgeois M. Complete AV‐block in two children with immunohistochemical proven myocarditis. Eur J Pediatr 1996 Aug;155:633‐636. doi:10.1007/BF01957142
Bariani R, Cipriani A, Rizzo S, Celeghin R, BuenoMarinas M, Giorgi B, et al. ‘Hot phase’ clinical presentation in arrhythmogeniccardiomyopathy. Europace 2021;23:907‐917. doi:10.1093/europace/euaa343
Lota AS, Hazebroek MR, Theotokis P, Wassall R, Salmi S, Halliday BP, et al. Genetic architecture of acute myocarditis and the overlap with inherited cardiomyopathy. Circulation 2022;146:1123‐1134. doi:10.1161/CIRCULATIONAHA.121.058457
Glikson M, Nielsen JC, Kronborg MB, Nielsen JC. ESC Scientific Document Group. 2021 ESC guidelines on cardiac pacing and cardiac resynchronization therapy. Eur Heart J 2021;42:3427‐3520. doi:10.1093/eurheartj/ehab699
Lazzerini PE, MurthyGinjupalli VK, Srivastava U, Bertolozzi I, Bacarelli MR, Verrengia D, et al. Anti‐Ro/SSA antibodies blocking calcium channels as a potentially reversible cause of atrioventricular block in adults. JACC Clin Electrophysiol 2023;9:1631‐1648. doi:10.1016/j.jacep.2023.03.007